Incyte Corporation vs Moderna, Inc.
A head-to-head of Incyte Corporation (INCY) and Moderna, Inc. (MRNA) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.
| Metric | INCY | MRNA |
|---|---|---|
| Market Cap | $23.42B | $24.53B |
| P/E (TTM) | 16.56 | — |
| Forward P/E | 10.52 | -10.81 |
| P/S | 3.55 | 8.44 |
| P/B | 4.17 | 3.29 |
| EV/EBITDA | 9.71 | -6.46 |
| Dividend Yield | — | — |
| Profit Margin | 26.71% | -144.92% |
| Gross Margin | 92.76% | 54.84% |
| Operating Margin | 26.12% | -159.94% |
| Revenue Growth (YoY) | +20.87% | +263.55% |
| FCF Yield | 7.47% | -8.54% |
| Debt / Equity | 0.70 | 7.96 |
| Current Ratio | 3.68 | 2.41 |
Which is better: Incyte Corporation or Moderna, Inc.?
- ✓Larger by market cap: Moderna, Inc.
- ✓More profitable (net margin): Incyte Corporation
- ✓Faster revenue growth: Moderna, Inc.
- ✓Higher free-cash-flow yield: Incyte Corporation
Across 9 available metrics, Incyte Corporation leads 7–2.
There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.
Share:
Compare Incyte Corporation with others
This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.